Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.39 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.39 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.38 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30678658 | 1.00 | FPR2 (0.44) | FPR2CHRM1AKR1A1CHRM3HTR2A | |
| Hydrochloric Acid SCHEMBL312730 | 0.98 | FPR2 (0.43) | FPR2CHRM1AKR1A1CHRM3HTR2A | |
| Hydrochloric Acid SCHEMBL368540 | 0.98 | FPR2 (0.43) | FPR2CHRM1AKR1A1CHRM3HTR2A | |
| Trifluoroacetic Acid SCHEMBL6761033 | 0.90 | CA12 (0.38) | FPR2CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL5536883 | 0.89 | NOD1 (0.50) | HDAC2NOD1MMEFOLH1SLC1A3 | |
| SCHEMBL1298940 | 0.87 | NOD1 (0.53) | NOD1FOLH1GRIK1SLC1A2SLC1A1 | |
| Hydrochloric Acid SCHEMBL11572211 | 0.87 | NOD1 (0.49) | HDAC2NOD1MMEFOLH1SLC1A3 | |
| SCHEMBL4332338 | 0.86 | CA1 (0.36) | FPR2CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL4320796 | 0.86 | CA1 (0.36) | FPR2CHRM1AKR1A1CHRM3HTR2A | |
| SCHEMBL7719713 | 0.86 | CA1 (0.36) | FPR2CHRM1AKR1A1CHRM3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109387587-A | A kind of detection method of L-Arginine enantiomter | 广东盛泰华生物制药有限公司 | 2019-02-26 | — | — | CN | claimed |
| EP-3065730-A1 | VASODILATOR FORMULATION AND METHOD OF USE | Atp Institute Pty Ltd. (AU) | 2016-09-14 | — | — | EP | claimed |
| WO-2015061860-A1 | VASODILATOR FORMULATION AND METHOD OF USE | ATP INSTITUTE PTY LTD (AU) | 2015-05-07 | — | — | WO | claimed |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-03-20 | — | — | US | claimed |
| US-20250241848-A1 | NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR | ANTERIOS, INC. (US) | 2025-07-31 | — | — | US | disclosed |
| CN-119875982-A | Bacillus methanolica for producing L-arginine and construction method and application thereof | 天津科技大学 | 2025-04-25 | — | — | CN | disclosed |
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20220387299-A1 | NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR | ANTERIOS, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220175634-A1 | PEPTIDE NANOPARTICLES AND USES THEREFOR | ANTERIOS, INC. (US) | 2022-06-09 | — | — | US | disclosed |
| CN-107072974-B | Composition for promoting longitudinal bone growth comprising L-arginine and extract of Acanthopanax sessiliflorus | 庆熙大学校产学协力团 | 2021-03-26 | — | — | CN | disclosed |
| EP-3678700-A1 | COMPOUNDS FOR REDUCING THE VISCOSITY OF BIOLOGICAL FORMULATIONS | Merck Sharp & Dohme Corp. (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-0767792-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-11-20 | — | — | EP | disclosed |
| US-5977101-A | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
| EP-0869787-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 1999-03-24 | — | — | EP | disclosed |
| EP-0869787-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1998-10-14 | — | — | EP | disclosed |
| WO-1997024119-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| EP-0767792-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-04-16 | — | — | EP | disclosed |
| WO-1996000730-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1996-01-11 | — | — | WO | disclosed |
| WO-1994028028-A1 | TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES | SELECTIDE CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230022724-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | FPR2 3363/4885CHRM1 933/4885AKR1A1 1151/4885 |
| US-20250241848-A1 | NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR | TSG101, NPC1L1, NPC1 | FPR2 2286/4885CHRM1 4873/4885AKR1A1 2284/4885 |
| US-20220175634-A1 | PEPTIDE NANOPARTICLES AND USES THEREFOR | NGLY1, SPPL2B, TFIP11 | FPR2 294/4885CHRM1 4691/4885AKR1A1 3483/4885 |
| US-20230011869-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, O60361, MYD88 | FPR2 3363/4885CHRM1 933/4885AKR1A1 1151/4885 |
| US-20220387299-A1 | NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR | TSG101, NPC1L1, NPC1 | FPR2 2286/4885CHRM1 4873/4885AKR1A1 2284/4885 |
| US-20140080788-A1 | NOVEL BICYCLIC NITROGEN CONTAINING HETEROARYL TGR5 RECEPTOR MODULATORS | GRK5, GPBAR1, GPR55 | FPR2 975/4885CHRM1 114/4885AKR1A1 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.